ADAR1 Capital Management, LLC bought $722K of InMed Pharmaceuticals (INM)
Executed May 19, disclosed May 21, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 21), the stock returned -3.2% (delay-adjusted); from the execution session (May 19), -16.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
ADAR1 Capital Management, LLC (10% owner) filed 9 Form 4 reports as a reporting entity in the trailing twelve months (9 purchases, 0 sales), most often in Rallybio Corporation (RLYB). Across 6 priced purchase filings, the average 21-session return was +9.6% from execution and +15.9% from disclosure (delay-adjusted; derived). The largest single filing was $2.1M of RLYB (152,005 sh across 2 lots, as filed), executed May 4.
Healthcare · InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→